ArticleResearch square2026
Allostatic Load Predicts Symptom Burden Among Breast Cancer Survivors.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer survivors frequently experience persistent and co-occurring symptoms, yet the role of allostatic load (AL), a measure of cumulative physiological stress, in shaping these outcomes remains unclear. We examined the associations of AL with physical and mental health outcomes, symptom burden profiles, and socioeconomic disparities among breast cancer survivors using data from the UK Biobank. The study included 1,444 breast cancer survivors and 1,444 age-matched women without cancer who completed baseline (2006-2010) and follow-up (2022) assessments. AL was derived from 11 biomarkers and analyzed as a continuous measure. Survivorship outcomes included sleep quality, fatigue, depression, anxiety, cognitive function, functional limitation, and self-rated mental health. Latent class analysis was used to identify symptom burden profiles, and multivariable regression and mediation analyses were performed. Among breast cancer survivors (mean age 58 years), higher AL was associated with poorer sleep quality (β = 0.18, 95% CI 0.06-0.29), greater fatigue (β = 0.23, 95% CI 0.12-0.35), increased functional limitation (β = 0.28, 95% CI 0.09-0.47), higher depressive symptoms (β = 0.15, 95% CI 0.02-0.28), higher anxiety (β = 0.12, 95% CI 0.01-0.23), and poorer self-rated mental health (β = -0.09, 95% CI - 0.13 to - 0.05), but not cognitive function. These associations were weaker or absent among women without cancer. Higher AL was also associated with increased likelihood of adverse symptom burden profiles. Mediation analyses indicated that AL partially mediated associations of income and education with multiple outcomes, accounting for approximately 6-15% and 8-9% of these associations, respectively. These findings suggest that elevated AL is associated with worse survivorship outcomes and contributes to socioeconomic disparities in symptom burden among breast cancer survivors. Chronic physiological stress may represent an important mechanism underlying survivorship heterogeneity and a potential target for intervention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.